These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22456540)

  • 1. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
    Llácer Delicado T; Torrecilla E; Holguín Á
    J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
    Han YS; Mesplède T; Wainberg MA
    Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    Oliveira M; Ibanescu RI; Pham HT; Brenner B; Mesplède T; Wainberg MA
    AIDS; 2016 Sep; 30(15):2267-73. PubMed ID: 27367488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.